Leon-nanodrugs GmbH (LEON), a pharmatech firm specializing within the improvement of nanoencapsulation methods for genetic materials and different lively substances, introduced at the moment the closing of a Sequence D financing spherical. New lead investor LBBW Enterprise Capital closed the spherical along with new traders and present shareholders like Albany Personal Fairness Holdings Pty Ltd., CD-Enterprise GmbH, Eckenstein-Geigy-Stiftung, Signet Healthcare Companions, TVM Life Science Innovation I L.P., and others.
“I am very pleased that we have completed this financing in the planned amount. The new funds will be used to augment the product portfolio. Our portfolio of leading equipment is designed to serve the Cell & Gene Therapy industry, enabling highly economic GMP manufacturing of small and individualized batches of nanoencapsulated Cell & Gene Therapies. Together with the financing, this puts us in a good position to select the best possible strategic partner to bring those products to the market”, commented Christian Nafe, Managing Director & CFO of LEON.
LEON’s strongly differentiated methods provide important USP’s filling present business gaps:
- NANOscreen: bench-top system for simplified formulation screening
- NANOlab®: bench-top system for quick and environment friendly course of improvement
- NANOme® : aseptic manufacturing system for prime throughput small- and individualized scale
- GMP manufacturing requiring no cleansing and sterilization resulting from a single use part
- NANOus® : giant scale manufacturing unit for business, sterile GMP batches.
The underlying FR-JET® reactor expertise is ready for future versatility of provider materials, and is optimized for minimal batch losses, and no scaling out. It’s included in all NANO-systems permitting to seamlessly scale up from course of improvement to business manufacturing.
Dr. Frank Mühlenbeck, representing lead investor LBBW Enterprise Capital, will be a part of LEON’s Supervisory Board. He acknowledged: “LEON’s products allow the efficient development and production of new, upcoming modalities in the biopharma industry including LNP’s with a special focus on decentralized patient-specific treatments. In addition to this bench-to-bedside approach, LEON’s products also empower CDMOs offering centralized manufacturing of such treatments. We completely understand the industry need for next-generation manufacturing solutions and are glad to support LEON in their effort to advance their products to commercialization.”
Dr. Hubert Birner, Managing Associate at TVM Life Science Administration and Chairman of LEON’s Supervisory Board acknowledged: “As a long-standing investor in LEON, we welcome the investment of LBBW VC, as it comes at a pivotal time for LEON to facilitate use of our lead products in the market. While medicine of today embraces more and more Cell & Gene Therapies, a smart solution for cost-efficient, fast and yet reliable and safe manufacturing is still required.”